Patent: 10,478,471
✉ Email this page to a colleague
Summary for Patent: 10,478,471
| Title: | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| Abstract: | A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. |
| Inventor(s): | Fritsche; Jens (Dusslingen, DE), Weinschenk; Toni (Aichwald, DE), Walter; Steffen (Reutingen, DE), Lewandrowski; Peter (Tuebingen-Hirschau, DE), Singh; Harpreet (Munich, DE) |
| Assignee: | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) |
| Application Number: | 16/502,268 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,478,471
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2030-03-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
